Sanofi jump­starts ef­fort to sup­ply 30 'essen­tial' drugs to low­er-in­come coun­tries

A week af­ter Sanofi promised to cut in­sulin prices, the phar­ma gi­ant’s non­prof­it unit is of­fer­ing more de­tails on its ef­fort to make the life-sav­ing drug and 29 oth­ers avail­able to 40 low­er-in­come coun­tries.

To­geth­er, the med­i­cines will form what Sanofi calls the Im­pact brand. They cov­er a range of dis­eases, from di­a­betes to car­dio­vas­cu­lar dis­ease to can­cer, and are con­sid­ered es­sen­tial by the World Health Or­ga­ni­za­tion, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER